☰

Mark J. Niciu - Publications

Affiliations: 
Yale University, New Haven, CT 
Area:
Addiction Psychiatry, Psychiatric Co-Morbidity, Copper Biology, Neuropeptide
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Niciu MJ, Meisner RC, Carr BR, Farooqui AA, Feifel D, Kaplin A, Kendrick EJ, Kim PM, Schneck CD, Vande Voort JL, Parikh SV. National network of depression centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder. Journal of Affective Disorders. PMID 37940059 DOI: 10.1016/j.jad.2023.11.008  0.416
2022 Alario AA, Niciu MJ. (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy. Chronic Stress (Thousand Oaks, Calif.). 6: 24705470221128017. PMID 36276228 DOI: 10.1177/24705470221128017  0.43
2021 Alario AA, Niciu MJ. Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology. Chronic Stress (Thousand Oaks, Calif.). 5: 24705470211014210. PMID 34159281 DOI: 10.1177/24705470211014210  0.407
2019 Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, Niciu MJ, Furey ML, Duncan WC, Zarate CA. Correction. Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder The Journal of Clinical Psychiatry. 77: e1655. PMID 28086017 DOI: 10.4088/JCP.16lcx11319  0.372
2019 Johnson IN, Shovestul BJ, Niciu MJ, Li F, Bloch MH. 1.60 ANTIDEPRESSANT TREATMENT OF MDD IN PATIENTS WITH COMORBID ALCOHOL USE DISORDER: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS WITH DISCUSSION OF PEDIATRIC IMPLICATIONS Journal of the American Academy of Child & Adolescent Psychiatry. 58: S166. DOI: 10.1016/J.Jaac.2019.08.082  0.354
2018 Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, Machado-Vieira R, Yuan P, Niciu MJ, Lyoo CH, Henter ID, Salvadore G, Drevets WC, Kolb H, Innis RB, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. Ejnmmi Research. 8: 57. PMID 29971587 DOI: 10.1186/S13550-018-0401-9  0.444
2018 Kadriu B, Yuan S, Farmer C, Nugent AC, Lener MS, Niciu MJ, Park M, Yazdian A, Ballard ED, Henn FA, Henter ID, Park LT, Zarate CA. Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology. PMID 29601316 DOI: 10.1097/Jcp.0000000000000866  0.431
2018 Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard ED, Zarate CA. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders. 232: 310-315. PMID 29501990 DOI: 10.1016/J.Jad.2018.02.049  0.461
2018 Ballard ED, Yarrington JS, Farmer CA, Lener MS, Kadriu B, Lally N, Williams D, Machado-Vieira R, Niciu MJ, Park L, Zarate CA. Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders. 231: 51-57. PMID 29448238 DOI: 10.1016/J.Jad.2018.01.027  0.487
2017 Niciu MJ, Iadarola ND, Banerjee D, Luckenbaugh DA, Park M, Lener M, Park L, Ionescu DF, Ballard ED, Brutsche NE, Akula N, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. Journal of Psychopharmacology (Oxford, England). 269881117732514. PMID 29039254 DOI: 10.1177/0269881117732514  0.479
2017 Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Henter ID, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA. Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Molecular Psychiatry. PMID 28555075 DOI: 10.1038/Mp.2017.109  0.335
2017 Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, Ameli R, Niciu MJ, Brutsche NE, Park L, Zarate CA. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. Journal of Affective Disorders. 218: 195-200. PMID 28477497 DOI: 10.1016/J.Jad.2017.04.057  0.414
2017 Kadriu B, Gold P, Lener M, Ballard E, Niciu M, Yuan P, Luckenbaugh D, Machado-Vieira R, Zarate C. 1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression Biological Psychiatry. 81: S405-S406. DOI: 10.1016/J.Biopsych.2017.02.730  0.397
2017 Ballard E, Luckenbaugh D, Yarrington J, Lally N, Lener M, Machado-Vieira R, Kadriu B, Niciu M, Park L, Zarate C. 330. A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression Biological Psychiatry. 81: S135. DOI: 10.1016/J.Biopsych.2017.02.345  0.463
2017 Shovestul B, Jaso B, Luckenbaugh D, Park L, Niciu M, Zarate C. 199. Associations between Specific Dissociative Symptoms and Symptom Subsets and Anti-Depressant Response to Ketamine Biological Psychiatry. 81: S82-S83. DOI: 10.1016/J.Biopsych.2017.02.212  0.393
2016 Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, Park LT, Machado-Vieira R, Duncan WC, Zarate CA. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. The Journal of Clinical Psychiatry. PMID 27929610 DOI: 10.4088/Jcp.15M10440  0.485
2016 Pennybaker SJ, Niciu MJ, Luckenbaugh DA, Zarate CA. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Journal of Affective Disorders. PMID 27839782 DOI: 10.1016/J.Jad.2016.10.026  0.515
2016 Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, Telu S, Hines CS, Pike VW, Zarate CA, Innis RB. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Molecular Psychiatry. PMID 27725657 DOI: 10.1038/Mp.2016.171  0.451
2016 Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, Zarate CA. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biological Psychiatry. PMID 27449797 DOI: 10.1016/J.Biopsych.2016.05.005  0.509
2016 Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, Niciu MJ, Furey ML, Duncan WC, Zarate CA. Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. The Journal of Clinical Psychiatry. 77: 825-831. PMID 27337418 DOI: 10.4088/Jcp.15M09943  0.345
2016 Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter ID, De Sousa RT, Niciu MJ, Yuan P, Zarate CA. The role of adipokines in the rapid antidepressant effects of ketamine. Molecular Psychiatry. PMID 27046644 DOI: 10.1038/Mp.2016.36  0.479
2016 Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, Ballard ED, Nugent AC, Machado-Vieira R, Zarate CA. THERAPEUTIC MODULATION OF GLUTAMATE RECEPTORS IN MAJOR DEPRESSIVE DISORDER. Current Neuropharmacology. PMID 26997505 DOI: 10.2174/1570159X14666160321123221  0.404
2016 Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology. PMID 26728893 DOI: 10.1007/S00213-015-4195-4  0.465
2016 Park M, Niciu MJ, Zarate CA. Erratum to: Novel Glutamatergic Treatments for Severe Mood Disorders Current Behavioral Neuroscience Reports. 3: 86-86. DOI: 10.1007/S40473-016-0069-2  0.369
2015 Park M, Niciu MJ, Zarate CA. Novel Glutamatergic Treatments for Severe Mood Disorders. Current Behavioral Neuroscience Reports. 2: 198-208. PMID 26824031 DOI: 10.1007/S40473-015-0050-5  0.437
2015 Zarate CA, Niciu MJ. Ketamine for depression: evidence, challenges and promise. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 14: 348-50. PMID 26407791 DOI: 10.1002/Wps.20269  0.55
2015 Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. Journal of Affective Disorders. 187: 241-4. PMID 26363143 DOI: 10.1016/J.Jad.2015.08.026  0.432
2015 Ballard ED, Luckenbaugh DA, Richards EM, Walls TL, Brutsché NE, Ameli R, Niciu MJ, Vande Voort JL, Zarate CA. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. Journal of Psychiatric Research. 68: 68-73. PMID 26228403 DOI: 10.1016/J.Jpsychires.2015.06.003  0.403
2015 Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plasticity. 2015: 858251. PMID 26137324 DOI: 10.1155/2015/858251  0.489
2015 Iadarola ND, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic Advances in Chronic Disease. 6: 97-114. PMID 25954495 DOI: 10.1177/2040622315579059  0.506
2015 Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology (Oxford, England). 29: 596-607. PMID 25691504 DOI: 10.1177/0269881114568041  0.502
2015 Ionescu DF, Nugent AC, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA, Furey ML. Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. Acta Neuropsychiatrica. 27: 143-52. PMID 25600154 DOI: 10.1017/Neu.2014.46  0.502
2015 Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders. 17: 438-43. PMID 25400146 DOI: 10.1111/Bdi.12277  0.535
2014 Niciu MJ, Mathews DC, Ionescu DF, Richards EM, Furey ML, Yuan P, Nugent AC, Henter ID, Machado-Vieira R, Zarate CA. Biomarkers in mood disorders research: developing new and improved therapeutics. Revista De Psiquiatria Clinica. 41: 131-134. PMID 26082563 DOI: 10.1590/0101-60830000000027  0.333
2014 Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18. PMID 25539512 DOI: 10.1093/Ijnp/Pyu039  0.461
2014 Ortiz R, Niciu MJ, Lukkahati N, Saligan LN, Nugent AC, Luckenbaugh DA, Machado-Vieira R, Zarate CA. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. Journal of Affective Disorders. 172: 307-311. PMID 25451430 DOI: 10.1016/J.Jad.2014.09.015  0.44
2014 Ionescu DF, Niciu MJ, Richards EM, Zarate CA. Pharmacologic treatment of dimensional anxious depression: a review. The Primary Care Companion For Cns Disorders. 16. PMID 25317369 DOI: 10.4088/Pcc.13R01621  0.467
2014 Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. The Journal of Clinical Psychiatry. 75: e932-8. PMID 25295436 DOI: 10.4088/Jcp.14M09049  0.52
2014 Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsché NE, Ameli R, Furey ML, Zarate CA. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. Journal of Psychiatric Research. 58: 161-6. PMID 25169854 DOI: 10.1016/J.Jpsychires.2014.07.027  0.486
2014 Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. Journal of Psychiatric Research. 58: 197-9. PMID 25139008 DOI: 10.1016/J.Jpsychires.2014.07.022  0.4
2014 Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G. Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychotherapy and Psychosomatics. 83: 298-307. PMID 25116726 DOI: 10.1159/000361078  0.4
2014 Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Brutsche NE, Machado-Vieira R, Zarate CA. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 47: 141-4. PMID 24955551 DOI: 10.1055/S-0034-1377042  0.476
2014 Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA. Clinical predictors of ketamine response in treatment-resistant major depression. The Journal of Clinical Psychiatry. 75: e417-23. PMID 24922494 DOI: 10.4088/Jcp.13M08698  0.49
2014 Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA. Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders. 159: 56-61. PMID 24679390 DOI: 10.1016/J.Jad.2014.02.017  0.463
2014 Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annual Review of Pharmacology and Toxicology. 54: 119-39. PMID 24392693 DOI: 10.1146/Annurev-Pharmtox-011613-135950  0.497
2014 Niciu MJ, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM, Machado-Vieira R, Zarate CA. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depression and Anxiety. 31: 297-307. PMID 24353110 DOI: 10.1002/Da.22224  0.345
2014 Niciu MJ, Ionescu DF, Richards EM, Zarate CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. Journal of Neural Transmission (Vienna, Austria : 1996). 121: 907-24. PMID 24318540 DOI: 10.1007/S00702-013-1130-X  0.501
2014 Niciu MJ, Henter ID, Sanacora G, Zarate CA. Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity? The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 15: 2-16. PMID 24024876 DOI: 10.3109/15622975.2013.829585  0.465
2014 Ballard ED, Voort JV, Luckenbaugh DA, Richards EM, Ionescu DF, Niciu MJ, Brutsche NE, Ameli R, Zarate CA. Suicidal ideation in the context of ketamine infusion: Relationship with depression and anxiety symptom clusters Comprehensive Psychiatry. 55: e45. DOI: 10.1016/J.Comppsych.2014.08.002  0.437
2013 Mathews DC, Richards EM, Niciu MJ, Ionescu DF, Rasimas JJ, Zarate CA. NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER. Translational Neuroscience. 4. PMID 24294519 DOI: 10.2478/S13380-013-0120-7  0.339
2013 Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Zarate CA. Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biological Psychiatry. 74: e23-4. PMID 23726512 DOI: 10.1016/J.Biopsych.2013.01.038  0.422
2013 Niciu MJ, Grunschel BD, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. Journal of Psychopharmacology (Oxford, England). 27: 651-4. PMID 23676198 DOI: 10.1177/0269881113486718  0.55
2013 Ionescu DF, Niciu MJ, Henter ID, Zarate CA. Defining anxious depression: a review of the literature. Cns Spectrums. 18: 252-60. PMID 23507190 DOI: 10.1017/S1092852913000114  0.509
2013 Ionescu DF, Niciu MJ, Mathews DC, Richards EM, Zarate CA. Neurobiology of anxious depression: a review. Depression and Anxiety. 30: 374-85. PMID 23495126 DOI: 10.1002/Da.22095  0.506
2013 Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. Cns Spectrums. 18: 242-51. PMID 23472710 DOI: 10.1017/S1092852913000138  0.398
2013 Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. Cns Spectrums. 18: 231-41. PMID 23462230 DOI: 10.1017/S1092852913000059  0.444
2012 Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacology, Biochemistry, and Behavior. 100: 656-64. PMID 21889952 DOI: 10.1016/J.Pbb.2011.08.008  0.311
2009 Niciu MJ, Chan G, Gelernter J, Arias AJ, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR. Subtypes of major depression in substance dependence. Addiction (Abingdon, England). 104: 1700-9. PMID 19681804 DOI: 10.1111/J.1360-0443.2009.02672.X  0.437
Show low-probability matches.